06 August 2026
06 August 2026
Alteogen is set to receive an upfront payment and could earn additional amounts through development, regulatory, and sales milestone payments.
The integration is intended to ensure patients identified through imaging are guided and supported along the appropriate pathway.
The trail will evaluate the BL-M14D1 regimen compared to standard treatment.
The planned trial aims to enrol at least 15 participants and is expected to begin in the fourth quarter of 2026.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
